ELDECORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELDECORT (ELDECORT).
Corticosteroid binding to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of cytokine production.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized by other CYP450 enzymes; undergoes reduction and conjugation; small amount reduced to prednisolone. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination contributes about 30% due to biliary secretion; the remaining 10% is metabolized. |
| Half-life | Terminal elimination half-life is 3.5 ± 1.2 hours in adults with normal renal function; prolonged to 6–8 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 92% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | 0.20–0.25 L/kg, indicating moderate distribution into total body water; lower in obese patients (0.15 L/kg). |
| Bioavailability | Oral: 85–90%; intramuscular: 100%; intravenous: 100%. |
| Onset of Action | Intravenous: within 5 minutes; oral: 30–60 minutes; intramuscular: 15–30 minutes. |
| Duration of Action | Intravenous: 4–6 hours; oral: 6–8 hours; intramuscular: 8–12 hours; duration is dose-dependent and extended in hepatic impairment. |
| Molecular Weight | 360.44 |
Initial: 5-60 mg orally once daily, adjusted based on response; typical maintenance: 5-15 mg orally once daily.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustment required for renal impairment; monitor for fluid retention and hypertension. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50%. Child-Pugh Class C: Avoid use or reduce dose by 75% with close monitoring. |
| Pediatric use | 0.1-2 mg/kg/day orally in divided doses every 6-12 hours; maximum 60 mg/day. |
| Geriatric use | Start at lowest effective dose (e.g., 2.5-5 mg/day); monitor for osteoporosis, hyperglycemia, and immunosuppression. |
| 1st trimester | Risk of fetal harm (cleft palate, growth restriction). Use only if maternal benefit outweighs risk. |
| 2nd trimester | Risk of fetal growth restriction and adrenal suppression. Use only if maternal benefit outweighs risk. |
| 3rd trimester | Risk of neonatal adrenal suppression and premature delivery. Use only if maternal benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for ELDECORT (ELDECORT).
| Placental transfer | Readily crosses the placenta; rapidly converted to prednisolone which crosses to a lesser extent. |
| Breastfeeding | Corticosteroids are excreted in breast milk. High doses may cause growth suppression or adrenal suppression in the infant. Use with caution; consider alternative agents. |
■ FDA Black Box Warning
May increase risk of opportunistic infections, including reactivation of latent tuberculosis and fungal infections. Avoid live vaccines during therapy. Corticosteroids can cause adrenal suppression upon withdrawal.
| Serious Effects |
Systemic fungal infectionHypersensitivity to any component
| Precautions | Adrenal suppression during stress or withdrawal; increased susceptibility to infections; masking of infection signs; gastrointestinal perforation; osteoporosis; ocular effects (cataracts, glaucoma); growth suppression in children; psychiatric disturbances; thromboembolic events; hypercorticism; potassium wasting. |
| Food/Dietary | Grapefruit and grapefruit juice may increase prednisolone levels. Avoid excessive salt intake to reduce fluid retention. Foods high in potassium (e.g., bananas, leafy greens) are recommended to counteract hypokalemia. Corticosteroids may increase blood glucose; limit simple sugars and carbohydrates in diabetic patients. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of orofacial clefts (odds ratio 1.3-3.4). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, oligohydramnios. Chronic use: Premature closure of ductus arteriosus, persistent pulmonary hypertension. |
| Fetal Monitoring | Maternal: Blood pressure, blood glucose, weight gain, signs of infection. Fetal: Serial ultrasound for growth, amniotic fluid index, ductus arteriosus Doppler if used >2 weeks after 20 weeks. |
| Fertility Effects | May inhibit ovulation at high doses via suppression of hypothalamic-pituitary-ovarian axis; reversible upon discontinuation. |
| Clinical Pearls | ELDECORT (prednisolone) is a corticosteroid with strong anti-inflammatory and immunosuppressive properties. Monitor for hyperglycemia, especially in diabetic patients. Use lowest effective dose for shortest duration to minimize adrenal suppression. Taper dose when discontinuing to avoid acute adrenal insufficiency. Watch for increased susceptibility to infections; avoid live vaccines. May mask signs of infection. Concomitant use with NSAIDs increases risk of GI bleeding. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · May cause increased appetite, weight gain, and fluid retention. · Report any signs of infection (fever, sore throat) or unusual bruising/bleeding. · Avoid close contact with people who have chickenpox or measles. · Limit sodium intake and eat potassium-rich foods (bananas, oranges). · May cause mood changes, insomnia, or irritability. · Do not receive live vaccines during treatment. · Wear a medical alert bracelet indicating you are taking corticosteroids. |